anti fibulin 3  (ProSci Incorporated)


Bioz Verified Symbol ProSci Incorporated is a verified supplier
Bioz Manufacturer Symbol ProSci Incorporated manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    ProSci Incorporated anti fibulin 3
    (A) Mutation of GLuc to eGLuc2 results in a more stable luminescent signal. HEK-293T cells were transfected with the indicated constructs, and conditioned media aliquots were assayed for GLuc activity. (B) Expression of eGLuc2 genes is tightly regulated and strongly inducible by doxycycline (dox) in Tet-On ARPE19 cells. Cells were cultured for 4 days in the presence (+) or absence (−) of 1 μg/mL dox, followed by a 24-h media change. eGLuc2 activity in the media after a total of 5 days expression was measured by the GLuc assay (n = 3, biological triplicates, ± SD). (C, D) Representative raw data from screening one 384-well Library of Pharmacologically Active Compounds (LOPAC) plate against cells expressing (C) wild-type (WT) <t>fibulin-3–eGLuc2</t> (WT-eGLuc2) or (D) R345W fibulin-3–eGLuc2 (R345W-eGLuc2). The average vehicle-treated control signal + 3 SD (green dashed line) or – 3 SD (red dashed line) is shown for each cell line. (E) The two fibulin-3–enhancing compounds and top 10 fibulin-3–reducing compounds are displayed (n = 3, ± SEM).
    Anti Fibulin 3, supplied by ProSci Incorporated, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti fibulin 3/product/ProSci Incorporated
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti fibulin 3 - by Bioz Stars, 2023-06
    93/100 stars

    Images

    1) Product Images from "A High-Throughput Cell-Based Gaussia Luciferase Reporter Assay for Identifying Modulators of Fibulin-3 Secretion"

    Article Title: A High-Throughput Cell-Based Gaussia Luciferase Reporter Assay for Identifying Modulators of Fibulin-3 Secretion

    Journal: Journal of biomolecular screening

    doi: 10.1177/1087057112469405

    (A) Mutation of GLuc to eGLuc2 results in a more stable luminescent signal. HEK-293T cells were transfected with the indicated constructs, and conditioned media aliquots were assayed for GLuc activity. (B) Expression of eGLuc2 genes is tightly regulated and strongly inducible by doxycycline (dox) in Tet-On ARPE19 cells. Cells were cultured for 4 days in the presence (+) or absence (−) of 1 μg/mL dox, followed by a 24-h media change. eGLuc2 activity in the media after a total of 5 days expression was measured by the GLuc assay (n = 3, biological triplicates, ± SD). (C, D) Representative raw data from screening one 384-well Library of Pharmacologically Active Compounds (LOPAC) plate against cells expressing (C) wild-type (WT) fibulin-3–eGLuc2 (WT-eGLuc2) or (D) R345W fibulin-3–eGLuc2 (R345W-eGLuc2). The average vehicle-treated control signal + 3 SD (green dashed line) or – 3 SD (red dashed line) is shown for each cell line. (E) The two fibulin-3–enhancing compounds and top 10 fibulin-3–reducing compounds are displayed (n = 3, ± SEM).
    Figure Legend Snippet: (A) Mutation of GLuc to eGLuc2 results in a more stable luminescent signal. HEK-293T cells were transfected with the indicated constructs, and conditioned media aliquots were assayed for GLuc activity. (B) Expression of eGLuc2 genes is tightly regulated and strongly inducible by doxycycline (dox) in Tet-On ARPE19 cells. Cells were cultured for 4 days in the presence (+) or absence (−) of 1 μg/mL dox, followed by a 24-h media change. eGLuc2 activity in the media after a total of 5 days expression was measured by the GLuc assay (n = 3, biological triplicates, ± SD). (C, D) Representative raw data from screening one 384-well Library of Pharmacologically Active Compounds (LOPAC) plate against cells expressing (C) wild-type (WT) fibulin-3–eGLuc2 (WT-eGLuc2) or (D) R345W fibulin-3–eGLuc2 (R345W-eGLuc2). The average vehicle-treated control signal + 3 SD (green dashed line) or – 3 SD (red dashed line) is shown for each cell line. (E) The two fibulin-3–enhancing compounds and top 10 fibulin-3–reducing compounds are displayed (n = 3, ± SEM).

    Techniques Used: Mutagenesis, Transfection, Construct, Activity Assay, Expressing, Cell Culture

    Dose-dependence confirmation of select fibulin-3–reducing compounds. ARPE19 cells expressing eGLuc2, wild-type (WT) fibulin-3–eGLuc2 (WT-eGLuc2), or R345W fibulin-3–eGLuc2 (R345W-eGLuc2) were treated with the indicated compounds for 24 h, after which the secreted (A, C, E) or intracellular accumulation of each eGLuc2 variant was measured (B, D, F). n = 3, ± SD.
    Figure Legend Snippet: Dose-dependence confirmation of select fibulin-3–reducing compounds. ARPE19 cells expressing eGLuc2, wild-type (WT) fibulin-3–eGLuc2 (WT-eGLuc2), or R345W fibulin-3–eGLuc2 (R345W-eGLuc2) were treated with the indicated compounds for 24 h, after which the secreted (A, C, E) or intracellular accumulation of each eGLuc2 variant was measured (B, D, F). n = 3, ± SD.

    Techniques Used: Expressing, Variant Assay

    Hit compounds alter the secretion of untagged fibulin-3. (A) ARPE19 cells were infected with adenovirus encoding for β-galactosidase (LacZ), untagged wild-type (WT) fibulin-3, untagged R345W fibulin-3, or untagged WT fibulin-5 (an approximate multiplicity of infection [MOI] of 50) for 48 h followed by 24 h treatment with the indicated compound (10 μM). Portions of the conditioned media after drug treatment were analyzed by Western blotting and probed with anti–fibulin-3 (FBLN3), anti-ERdj3, or anti–fibulin-5 (FBLN5) antibodies (representative data of three independent experiments). Endogenous ERdj3 was monitored in cells infected with WT fibulin-3 at an MOI of 50. (B) LI-COR quantification of the band intensity of conditioned media samples (n ≥ 3, ± SEM).
    Figure Legend Snippet: Hit compounds alter the secretion of untagged fibulin-3. (A) ARPE19 cells were infected with adenovirus encoding for β-galactosidase (LacZ), untagged wild-type (WT) fibulin-3, untagged R345W fibulin-3, or untagged WT fibulin-5 (an approximate multiplicity of infection [MOI] of 50) for 48 h followed by 24 h treatment with the indicated compound (10 μM). Portions of the conditioned media after drug treatment were analyzed by Western blotting and probed with anti–fibulin-3 (FBLN3), anti-ERdj3, or anti–fibulin-5 (FBLN5) antibodies (representative data of three independent experiments). Endogenous ERdj3 was monitored in cells infected with WT fibulin-3 at an MOI of 50. (B) LI-COR quantification of the band intensity of conditioned media samples (n ≥ 3, ± SEM).

    Techniques Used: Infection, Western Blot

    anti fibulin 3  (ProSci Incorporated)


    Bioz Verified Symbol ProSci Incorporated is a verified supplier
    Bioz Manufacturer Symbol ProSci Incorporated manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    ProSci Incorporated anti fibulin 3
    (A) Mutation of GLuc to eGLuc2 results in a more stable luminescent signal. HEK-293T cells were transfected with the indicated constructs, and conditioned media aliquots were assayed for GLuc activity. (B) Expression of eGLuc2 genes is tightly regulated and strongly inducible by doxycycline (dox) in Tet-On ARPE19 cells. Cells were cultured for 4 days in the presence (+) or absence (−) of 1 μg/mL dox, followed by a 24-h media change. eGLuc2 activity in the media after a total of 5 days expression was measured by the GLuc assay (n = 3, biological triplicates, ± SD). (C, D) Representative raw data from screening one 384-well Library of Pharmacologically Active Compounds (LOPAC) plate against cells expressing (C) wild-type (WT) <t>fibulin-3–eGLuc2</t> (WT-eGLuc2) or (D) R345W fibulin-3–eGLuc2 (R345W-eGLuc2). The average vehicle-treated control signal + 3 SD (green dashed line) or – 3 SD (red dashed line) is shown for each cell line. (E) The two fibulin-3–enhancing compounds and top 10 fibulin-3–reducing compounds are displayed (n = 3, ± SEM).
    Anti Fibulin 3, supplied by ProSci Incorporated, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti fibulin 3/product/ProSci Incorporated
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti fibulin 3 - by Bioz Stars, 2023-06
    93/100 stars

    Images

    1) Product Images from "A High-Throughput Cell-Based Gaussia Luciferase Reporter Assay for Identifying Modulators of Fibulin-3 Secretion"

    Article Title: A High-Throughput Cell-Based Gaussia Luciferase Reporter Assay for Identifying Modulators of Fibulin-3 Secretion

    Journal: Journal of biomolecular screening

    doi: 10.1177/1087057112469405

    (A) Mutation of GLuc to eGLuc2 results in a more stable luminescent signal. HEK-293T cells were transfected with the indicated constructs, and conditioned media aliquots were assayed for GLuc activity. (B) Expression of eGLuc2 genes is tightly regulated and strongly inducible by doxycycline (dox) in Tet-On ARPE19 cells. Cells were cultured for 4 days in the presence (+) or absence (−) of 1 μg/mL dox, followed by a 24-h media change. eGLuc2 activity in the media after a total of 5 days expression was measured by the GLuc assay (n = 3, biological triplicates, ± SD). (C, D) Representative raw data from screening one 384-well Library of Pharmacologically Active Compounds (LOPAC) plate against cells expressing (C) wild-type (WT) fibulin-3–eGLuc2 (WT-eGLuc2) or (D) R345W fibulin-3–eGLuc2 (R345W-eGLuc2). The average vehicle-treated control signal + 3 SD (green dashed line) or – 3 SD (red dashed line) is shown for each cell line. (E) The two fibulin-3–enhancing compounds and top 10 fibulin-3–reducing compounds are displayed (n = 3, ± SEM).
    Figure Legend Snippet: (A) Mutation of GLuc to eGLuc2 results in a more stable luminescent signal. HEK-293T cells were transfected with the indicated constructs, and conditioned media aliquots were assayed for GLuc activity. (B) Expression of eGLuc2 genes is tightly regulated and strongly inducible by doxycycline (dox) in Tet-On ARPE19 cells. Cells were cultured for 4 days in the presence (+) or absence (−) of 1 μg/mL dox, followed by a 24-h media change. eGLuc2 activity in the media after a total of 5 days expression was measured by the GLuc assay (n = 3, biological triplicates, ± SD). (C, D) Representative raw data from screening one 384-well Library of Pharmacologically Active Compounds (LOPAC) plate against cells expressing (C) wild-type (WT) fibulin-3–eGLuc2 (WT-eGLuc2) or (D) R345W fibulin-3–eGLuc2 (R345W-eGLuc2). The average vehicle-treated control signal + 3 SD (green dashed line) or – 3 SD (red dashed line) is shown for each cell line. (E) The two fibulin-3–enhancing compounds and top 10 fibulin-3–reducing compounds are displayed (n = 3, ± SEM).

    Techniques Used: Mutagenesis, Transfection, Construct, Activity Assay, Expressing, Cell Culture

    Dose-dependence confirmation of select fibulin-3–reducing compounds. ARPE19 cells expressing eGLuc2, wild-type (WT) fibulin-3–eGLuc2 (WT-eGLuc2), or R345W fibulin-3–eGLuc2 (R345W-eGLuc2) were treated with the indicated compounds for 24 h, after which the secreted (A, C, E) or intracellular accumulation of each eGLuc2 variant was measured (B, D, F). n = 3, ± SD.
    Figure Legend Snippet: Dose-dependence confirmation of select fibulin-3–reducing compounds. ARPE19 cells expressing eGLuc2, wild-type (WT) fibulin-3–eGLuc2 (WT-eGLuc2), or R345W fibulin-3–eGLuc2 (R345W-eGLuc2) were treated with the indicated compounds for 24 h, after which the secreted (A, C, E) or intracellular accumulation of each eGLuc2 variant was measured (B, D, F). n = 3, ± SD.

    Techniques Used: Expressing, Variant Assay

    Hit compounds alter the secretion of untagged fibulin-3. (A) ARPE19 cells were infected with adenovirus encoding for β-galactosidase (LacZ), untagged wild-type (WT) fibulin-3, untagged R345W fibulin-3, or untagged WT fibulin-5 (an approximate multiplicity of infection [MOI] of 50) for 48 h followed by 24 h treatment with the indicated compound (10 μM). Portions of the conditioned media after drug treatment were analyzed by Western blotting and probed with anti–fibulin-3 (FBLN3), anti-ERdj3, or anti–fibulin-5 (FBLN5) antibodies (representative data of three independent experiments). Endogenous ERdj3 was monitored in cells infected with WT fibulin-3 at an MOI of 50. (B) LI-COR quantification of the band intensity of conditioned media samples (n ≥ 3, ± SEM).
    Figure Legend Snippet: Hit compounds alter the secretion of untagged fibulin-3. (A) ARPE19 cells were infected with adenovirus encoding for β-galactosidase (LacZ), untagged wild-type (WT) fibulin-3, untagged R345W fibulin-3, or untagged WT fibulin-5 (an approximate multiplicity of infection [MOI] of 50) for 48 h followed by 24 h treatment with the indicated compound (10 μM). Portions of the conditioned media after drug treatment were analyzed by Western blotting and probed with anti–fibulin-3 (FBLN3), anti-ERdj3, or anti–fibulin-5 (FBLN5) antibodies (representative data of three independent experiments). Endogenous ERdj3 was monitored in cells infected with WT fibulin-3 at an MOI of 50. (B) LI-COR quantification of the band intensity of conditioned media samples (n ≥ 3, ± SEM).

    Techniques Used: Infection, Western Blot

    anti fibulin 3  (ProSci Incorporated)


    Bioz Verified Symbol ProSci Incorporated is a verified supplier
    Bioz Manufacturer Symbol ProSci Incorporated manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    ProSci Incorporated anti fibulin 3
    (A) Mutation of GLuc to eGLuc2 results in a more stable luminescent signal. HEK-293T cells were transfected with the indicated constructs, and conditioned media aliquots were assayed for GLuc activity. (B) Expression of eGLuc2 genes is tightly regulated and strongly inducible by doxycycline (dox) in Tet-On ARPE19 cells. Cells were cultured for 4 days in the presence (+) or absence (−) of 1 μg/mL dox, followed by a 24-h media change. eGLuc2 activity in the media after a total of 5 days expression was measured by the GLuc assay (n = 3, biological triplicates, ± SD). (C, D) Representative raw data from screening one 384-well Library of Pharmacologically Active Compounds (LOPAC) plate against cells expressing (C) wild-type (WT) <t>fibulin-3–eGLuc2</t> (WT-eGLuc2) or (D) R345W fibulin-3–eGLuc2 (R345W-eGLuc2). The average vehicle-treated control signal + 3 SD (green dashed line) or – 3 SD (red dashed line) is shown for each cell line. (E) The two fibulin-3–enhancing compounds and top 10 fibulin-3–reducing compounds are displayed (n = 3, ± SEM).
    Anti Fibulin 3, supplied by ProSci Incorporated, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti fibulin 3/product/ProSci Incorporated
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti fibulin 3 - by Bioz Stars, 2023-06
    93/100 stars

    Images

    1) Product Images from "A High-Throughput Cell-Based Gaussia Luciferase Reporter Assay for Identifying Modulators of Fibulin-3 Secretion"

    Article Title: A High-Throughput Cell-Based Gaussia Luciferase Reporter Assay for Identifying Modulators of Fibulin-3 Secretion

    Journal: Journal of biomolecular screening

    doi: 10.1177/1087057112469405

    (A) Mutation of GLuc to eGLuc2 results in a more stable luminescent signal. HEK-293T cells were transfected with the indicated constructs, and conditioned media aliquots were assayed for GLuc activity. (B) Expression of eGLuc2 genes is tightly regulated and strongly inducible by doxycycline (dox) in Tet-On ARPE19 cells. Cells were cultured for 4 days in the presence (+) or absence (−) of 1 μg/mL dox, followed by a 24-h media change. eGLuc2 activity in the media after a total of 5 days expression was measured by the GLuc assay (n = 3, biological triplicates, ± SD). (C, D) Representative raw data from screening one 384-well Library of Pharmacologically Active Compounds (LOPAC) plate against cells expressing (C) wild-type (WT) fibulin-3–eGLuc2 (WT-eGLuc2) or (D) R345W fibulin-3–eGLuc2 (R345W-eGLuc2). The average vehicle-treated control signal + 3 SD (green dashed line) or – 3 SD (red dashed line) is shown for each cell line. (E) The two fibulin-3–enhancing compounds and top 10 fibulin-3–reducing compounds are displayed (n = 3, ± SEM).
    Figure Legend Snippet: (A) Mutation of GLuc to eGLuc2 results in a more stable luminescent signal. HEK-293T cells were transfected with the indicated constructs, and conditioned media aliquots were assayed for GLuc activity. (B) Expression of eGLuc2 genes is tightly regulated and strongly inducible by doxycycline (dox) in Tet-On ARPE19 cells. Cells were cultured for 4 days in the presence (+) or absence (−) of 1 μg/mL dox, followed by a 24-h media change. eGLuc2 activity in the media after a total of 5 days expression was measured by the GLuc assay (n = 3, biological triplicates, ± SD). (C, D) Representative raw data from screening one 384-well Library of Pharmacologically Active Compounds (LOPAC) plate against cells expressing (C) wild-type (WT) fibulin-3–eGLuc2 (WT-eGLuc2) or (D) R345W fibulin-3–eGLuc2 (R345W-eGLuc2). The average vehicle-treated control signal + 3 SD (green dashed line) or – 3 SD (red dashed line) is shown for each cell line. (E) The two fibulin-3–enhancing compounds and top 10 fibulin-3–reducing compounds are displayed (n = 3, ± SEM).

    Techniques Used: Mutagenesis, Transfection, Construct, Activity Assay, Expressing, Cell Culture

    Dose-dependence confirmation of select fibulin-3–reducing compounds. ARPE19 cells expressing eGLuc2, wild-type (WT) fibulin-3–eGLuc2 (WT-eGLuc2), or R345W fibulin-3–eGLuc2 (R345W-eGLuc2) were treated with the indicated compounds for 24 h, after which the secreted (A, C, E) or intracellular accumulation of each eGLuc2 variant was measured (B, D, F). n = 3, ± SD.
    Figure Legend Snippet: Dose-dependence confirmation of select fibulin-3–reducing compounds. ARPE19 cells expressing eGLuc2, wild-type (WT) fibulin-3–eGLuc2 (WT-eGLuc2), or R345W fibulin-3–eGLuc2 (R345W-eGLuc2) were treated with the indicated compounds for 24 h, after which the secreted (A, C, E) or intracellular accumulation of each eGLuc2 variant was measured (B, D, F). n = 3, ± SD.

    Techniques Used: Expressing, Variant Assay

    Hit compounds alter the secretion of untagged fibulin-3. (A) ARPE19 cells were infected with adenovirus encoding for β-galactosidase (LacZ), untagged wild-type (WT) fibulin-3, untagged R345W fibulin-3, or untagged WT fibulin-5 (an approximate multiplicity of infection [MOI] of 50) for 48 h followed by 24 h treatment with the indicated compound (10 μM). Portions of the conditioned media after drug treatment were analyzed by Western blotting and probed with anti–fibulin-3 (FBLN3), anti-ERdj3, or anti–fibulin-5 (FBLN5) antibodies (representative data of three independent experiments). Endogenous ERdj3 was monitored in cells infected with WT fibulin-3 at an MOI of 50. (B) LI-COR quantification of the band intensity of conditioned media samples (n ≥ 3, ± SEM).
    Figure Legend Snippet: Hit compounds alter the secretion of untagged fibulin-3. (A) ARPE19 cells were infected with adenovirus encoding for β-galactosidase (LacZ), untagged wild-type (WT) fibulin-3, untagged R345W fibulin-3, or untagged WT fibulin-5 (an approximate multiplicity of infection [MOI] of 50) for 48 h followed by 24 h treatment with the indicated compound (10 μM). Portions of the conditioned media after drug treatment were analyzed by Western blotting and probed with anti–fibulin-3 (FBLN3), anti-ERdj3, or anti–fibulin-5 (FBLN5) antibodies (representative data of three independent experiments). Endogenous ERdj3 was monitored in cells infected with WT fibulin-3 at an MOI of 50. (B) LI-COR quantification of the band intensity of conditioned media samples (n ≥ 3, ± SEM).

    Techniques Used: Infection, Western Blot

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars

    • Image Search Results